Baricitinib for dermatitis

17th May 2021 by Dr Louise Hudman

Baricitinib for dermatitis

NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.

As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.

It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"LocumDeck does everything you want it to do in an instant and with audit trails.

I absolutely love the facility for receiving Locum's invoices and the facility for signing the Pension Forms electronically and they are then instantly sent with an audit trail! It is fabulous!

You are notified the moment a Locum GP adds availability which is just fantastic, I spend a lot of time just chasing agencies to see if they have availability, so to be notified the moment availability is advertised is a new concept and very welcome! I have no hesitation in recommending LocumDeck - it has already eased my workload!"

Sue, Practice Manager in Portsmouth

See the full list of features within our NASGP membership plans

Membership